Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, SA, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P, Holm, MS, Cazzola, M, Malcovati, L, Tauro, S, Bowen, D, Boultwood, J, Pellagatti, A, Pimanda, J, Unnikrishnan, A, Vyas, P, Göhring, G, Schlegelberger, B, Tobiasson, M, Kvalheim, G, Constantinescu, SN, Nerlov, C, Nilsson, L, Campbell, P, Sandberg, R, Papaemmanuil, E, Hellström-Lindberg, E, Linnarsson, S, Jacobsen, S
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Cell Press 2014

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Antzeko izenburuak